Scpharmaceuticals Inc (NASDAQ:SCPH) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price objective of $23.33 for the company and are anticipating that the company will post ($0.63) EPS for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 150 out of 265 based on the ratings given to its competitors.
Get Scpharmaceuticals alerts:Several equities research analysts have commented on SCPH shares. Zacks Investment Research lowered Scpharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Jefferies Group restated a “buy” rating and issued a $26.00 price objective on shares of Scpharmaceuticals in a research report on Wednesday, March 21st. Finally, ValuEngine upgraded Scpharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new stake in Scpharmaceuticals in the 1st quarter worth approximately $139,000. Schwab Charles Investment Management Inc. purchased a new stake in Scpharmaceuticals in the 1st quarter worth approximately $167,000. Monashee Investment Management LLC purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $230,000. Bank of New York Mellon Corp purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $414,000. Finally, Millennium Management LLC purchased a new stake in Scpharmaceuticals in the 4th quarter worth approximately $462,000. Institutional investors and hedge funds own 42.35% of the company’s stock.
Scpharmaceuticals traded down $0.31, reaching $13.07, during trading hours on Friday, according to MarketBeat Ratings. The stock had a trading volume of 96,208 shares, compared to its average volume of 145,218. The firm has a market cap of $242.34 million and a P/E ratio of -1.63. Scpharmaceuticals has a 52-week low of $8.89 and a 52-week high of $18.17. The company has a quick ratio of 19.23, a current ratio of 19.23 and a debt-to-equity ratio of 0.10.
Scpharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Monday, May 7th. The company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.04. research analysts expect that Scpharmaceuticals will post -2.91 earnings per share for the current year.
About Scpharmaceuticals
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment